1. Pink Sheet
  2. >>Biosimilars & Generics
  3. >>Generics

US FDA Floats Communications Upgrade For ANDAs With Missed Goals

 
• By Derrick Gingery

Sponsors of generic drug applications that miss a goal date, but do not receive an action because of complex scientific or legal questions, would get a notice outlining the lingering issue as part of a new pilot program that might become permanent in the next review cycle.

The OGD communications pilot could launch in November. (Shutterstock)

Generic drug sponsors may no longer have to wonder why an ANDA had not received a US Food and Drug Administration action if it continues to linger more than two months after its goal date.

Key Takeaways
  • The FDA will provide status updates to generic sponsors if complex issues delay an action as part of a new pilot program.

A pilot program potentially launching in November will improve communications in those situations. When a complex regulatory issue forces the...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Generics

FY 2025 Generic Drugs By The Numbers

 
• By Derrick Gingery

New FDA data shows a potentially concerning drop in ANDA submissions, while the first-cycle approval rate increased.

US FDA ANDA Priority Pilot ‘Practically Unusable’ Without Tweaks, AAM CEO Says

 
• By Sarah Karlin-Smith

Association for Accessible Medicines CEO John Murphy told the Pink Sheet that the FDA may need to consider phasing in the requirements for the new ANDA priority voucher incentive program if it wants sponsors to apply in the near-term.

Oz: CMS Developing Plans To Incentivize Domestic Manufacturing

 
• By Sarah Karlin-Smith

The Trump Administration’s efforts to encourage more US-based pharmaceutical manufacturing have largely centered on FDA plans and Trump’s threats of tariffs and Most Favored Nation pricing, but Oz hinted Medicare and Medicaid soon may soon announce new incentives.

GDUFA IV Talks Begin, Embracing Traditional Process

 
• By Derrick Gingery

The introductory meeting did not suggest changes to the expected schedule and operations for renewing the generic drug user fee, said AAM’s Giuseppe Randazzo.

More from Pathways & Standards

UK Targets Contamination Tests & Pharmacokinetic Studies In Animal Testing Phase Out

 
• By Eliza Slawther

Pharmaceutical companies will be expected to phase out certain animal tests in the drug development process under a UK roadmap aimed at pivoting towards using alternative models, such as organ-on-a-chip systems and artificial intelligence.

Proposed Shutdown-Ending Agreement Would Cut US FDA Non-User Fee Funding

 
• By Derrick Gingery

But the Senate’s reduction would not be as much as the House of Representatives and President Trump proposed earlier this year, which is likely a win for the agency.

How Regulatory Horizon Scanning Works In The EU, UK & Switzerland

 
• By Eliza Slawther

Horizon scanning is a tool used by regulators to prepare for forthcoming medicines that might challenge existing processes. Senior figures from the European Medicines Agency, Swissmedic and the UK MHRA explain how they conduct horizon scanning activities in their respective jurisdictions.